Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Alzheimer's Disease: Treatment

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Alzheimer's Disease: Overview

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...

Alzheimer Disease l: Introduction

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...

Alzheimer Disease ll: Pathophysiology

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Erratum: Diffusion MRI biomarkers predict the outcome of irreversible electroporation in a pancreatic tumor mouse model.

American journal of cancer research·2025

Same author

Dynamic Reconstruction of Ni/In<sub>2</sub>O<sub>3</sub>/ZrO<sub>2</sub> Catalyst in Reverse Water-Gas Conversion Reaction.

ChemSusChem·2025

Same author

A case report of a rare p phenotype individual and a review of molecular biological analysis of p phenotype in the Chinese population.

Transfusion medicine (Oxford, England)·2025

Same author

Multi-Scale Marine Object Detection in Side-Scan Sonar Images Based on BES-YOLO.

Sensors (Basel, Switzerland)·2024

Same author

Seipin deficiency-induced lipid dysregulation leads to hypomyelination-associated cognitive deficits via compromising oligodendrocyte precursor cell differentiation.

Cell death & disease·2024

Same author

Dual detection of Hg<sup>2+</sup> and Pb<sup>2+</sup> by a coumarin-functionalized Schiff base in environmental and biosystems.

Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy·2024

Search research articles

Related Experiment Video

Updated: May 19, 2026

Quantitative 3D In Silico Modeling (q3DISM) of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease

Quantitative 3D In Silico Modeling (q3DISM) of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease

Published on: December 26, 2016

Immunotherapy for Alzheimer's disease.

Weihua Wang¹, Liangfeng Fan, De'en Xu

¹Institute of Neuroscience, Soochow University, Suzhou, China.

Acta Biochimica Et Biophysica Sinica

|August 18, 2012

Summary

Alzheimer's disease (AD) immunotherapy targeting amyloid-beta (Aβ) shows limited cognitive benefits. Tau-based immunotherapies offer a promising new strategy for AD treatment, demonstrated in preclinical studies.

Related Experiment Videos

Last Updated: May 19, 2026

Quantitative 3D In Silico Modeling (q3DISM) of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease

Quantitative 3D In Silico Modeling (q3DISM) of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease

Published on: December 26, 2016

Area of Science:

Neuroscience
Immunology
Biochemistry

Background:

Alzheimer's disease (AD) is pathologically defined by amyloid-beta (Aβ) plaques and neurofibrillary tangles composed of hyperphosphorylated tau.
Both Aβ and tau pathologies are recognized as toxic in vitro and in vivo, driving neurodegeneration.

Purpose of the Study:

To review and summarize current immunotherapeutic strategies for Alzheimer's disease, focusing on targets Aβ and tau.
To evaluate the potential of Aβ and tau-based immunotherapies in preclinical and clinical settings.

Main Methods:

Review of existing literature on Aβ and tau immunotherapies for Alzheimer's disease.
Analysis of preclinical study outcomes and clinical trial data regarding efficacy and cognitive improvement.

Main Results:

Aβ immunotherapy has shown limited success in clinical trials for improving cognitive function.
Preclinical studies indicate that tau-targeted immunotherapies can effectively clear tau aggregates and enhance cognitive function.

Conclusions:

While Aβ immunotherapy faces challenges in clinical translation for cognitive enhancement, tau immunotherapy presents a novel and promising therapeutic avenue for Alzheimer's disease.
Further research into tau-based immunotherapies is warranted to explore their full potential in treating AD.